CytomX Therapeutics Inc
Closed
SectorHealthcare
3.58 -2.98
Overview
Share price change
24h
Min
3.54
Max
3.58
Income | 8.3M -18M |
|---|---|
Sales | 9.6M 10M |
P/E Sector Avg | 22.5 50.102 |
EPS | -0.1 |
Profit margin | -177.89 |
Employees | 69 |
EBITDA | 8M -19M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +231.54% upside |
Next Earnings | 6 sie 2026 |
|---|
Market Cap | -107M 803M |
|---|---|
Previous open | 6.56 |
Previous close | 3.58 |
CytomX Therapeutics Inc Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
CytomX Therapeutics Inc Forecast
Price Target
By TipRanks
231.54% upside
12 Months Forecast
Average 12.3 USD 231.54%
High 16 USD
Low 6 USD
Based on 10 Wall Street analysts offering 12 month price targets forCytomX Therapeutics Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About CytomX Therapeutics Inc
CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
